The potential role of biomarkers in HIV preventive vaccine trials.

Publication Type:

Journal Article


Journal of acquired immune deficiency syndromes (1999), Volume 51, Issue 5, p.536-45 (2009)


2009, AIDS Vaccines, Biological Markers, Clinical Trials as Topic, Female, HIV Infections, Humans, Male, Risk Factors, Vaccine and Infectious Disease Institute


Successful conduct of HIV vaccine efficacy trials entails identification and enrollment of at-risk populations, assessment of appropriate end points as measures of vaccine efficacy for prevention of HIV acquisition, and amelioration of disease course among infected vaccinees, as well as identification of potential confounders or effect modifiers. Although not invariably useful and bringing their own cost in terms of measurement and validation, a variety of biomarkers may aid at each stage of trial conduct.